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Introduction: Turoctocog alfa is a recombinant, B domain-truncated factor VIII (FVIII) 
approved for patients with haemophilia A.
Aim: To evaluate the safety and efficacy of turoctocog alfa in previously untreated 
patients (PUPs) with severe haemophilia A.
Methods: Guardian 4 was a multicentre, multinational, non-randomized, open-
label phase 3 trial comprising a main and extension phase. The former concluded 
once ≥ 50 patients had received treatment for ≥ 50 exposure days (EDs) or developed 
inhibitors. Patients received turoctocog alfa intravenously for prevention and treat-
ment of bleeds. The primary endpoint was the incidence rate of FVIII inhibitors (≥0.6 
Bethesda Units) reported during the first 50 EDs.
Results: Of the 58 patients who completed the main phase, 25 (43.1%) patients de-
veloped inhibitors (detected within 6-24 [mean: 14.2] EDs from treatment start). 
High-risk mutations were identified in 60% of patients who developed inhibitors in 
the main phase and were a significant predictor of inhibitor development (P = .003). 
Of the 21 patients who started immune tolerance induction therapy, 85.7% com-
pleted treatment with a negative inhibitor test (note that data on the last 3 patients 
completing ITI are based on information collated from sites prior to the final database 
lock). Haemostatic response (including missing values as failure) was rated as ‘excel-
lent’ or ‘good’ for 86.1% of bleeds occurring during prophylaxis. The estimated mean 
annualized bleeding rate for patients on prophylaxis was 4.26 bleeds/patient/year 
(95% CI: 3.34 − 5.44).
Conclusions: Turoctocog alfa was effective at preventing and stopping bleeds and 
was well tolerated. Inhibitor development was within the expected range for this 
PUP population.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes. 
© 2019 The Authors. Haemophilia published by John Wiley & Sons Ltd
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1  | INTRODUC TION
Turoctocog alfa is a third-generation, recombinant, B domain-trun-
cated human coagulation factor VIII (FVIII): the molecule has been 
discussed in detail elsewhere.1,2 Truncation of the B domain relative 
to endogenous FVIII has not been associated with any impact on the 
safety or efficacy of turoctocog alfa, which has demonstrated effi-
cacy and safety in Phase 3 trials in previously treated children, ado-
lescents and adults (guardian 1, 2 and 3 clinical trials). Reductions in 
annualized bleeding rate (ABR) were observed across all age groups 
with an overall median ABR of 1.37 bleeds/patient/year (3.7 and 3.0 
bleeds/patient/year reported for adolescents/adults and children 
on prophylaxis, respectively).3-5 Furthermore, no inhibitors were re-
ported in previously treated patients (PTPs) (N = 238) in clinical trials 
following treatment with turoctocog alfa with a cumulative of 856 
patient-years of exposure.3-5
Inhibitors occur most frequently in patients with severe haemo-
philia A,6 and the majority of patients who develop inhibitors are 
likely to do so within the first 50 exposure days (EDs) of treatment.7 
However, inhibitor formation can occur earlier and inhibitors have 
been detected as early as after 5 EDs.8 In single product and cohort 
studies of previously untreated patients (PUPs) with haemophilia A, 
inhibitors have been reported in up to 39% of patients.9-11 The aim 
of this trial was to evaluate the safety and efficacy of turoctocog alfa 
in PUPs with severe haemophilia A.
2  | MATERIAL S AND METHODS
2.1 | Trial design
Guardian 4 was a multicentre, multinational, non-randomized, 
open-label, safety and efficacy trial in a paediatric popula-
tion of PUPs with haemophilia A (NCT01493778). The trial in-
volved 40 participating sites in Algeria, Austria, China, Denmark, 
Greece, Hong Kong, Hungary, Japan, Lithuania, Poland, Russian 
Federation, Serbia, Spain, Turkey and the United States, and 
began on 17 September 2012. The Last Patient Last Visit was on 
27 June 2018.
The trial comprised two phases—a main phase and an exten-
sion phase. Once enrolled, five patient visits were scheduled (until 
the end of the main phase based on the number of EDs reached), 
including the screening visit (Visit 1) and four subsequent visits 
(Figure 1). Inhibitor testing was performed at three scheduled vis-
its: Visits 3, 4 and 5 (10-15, 20-25 and 50-55 EDs, respectively) and 
could be done at any unscheduled visit at the investigators’ dis-
cretion. The main phase of the trial concluded once ≥ 50 patients 
had received treatment for ≥ 50 EDs or developed FVIII inhibitors. 
Patients who developed inhibitors (confirmed by two positive con-
secutive tests, preferably within two weeks) during the main or 
extension phases of the trial could continue treatment with turoc-
tocog alfa, including immune tolerance induction (ITI). The trial was 
approved by all relevant independent ethics committees and in-
stitutional review boards. Written informed consent was obtained 
from all participants’ legally authorized representatives before any 
study-related activities commenced. The trial was conducted in 
accordance with the declaration of Helsinki12 and Good Clinical 
Practice.13
2.2 | Participants
Patients were eligible for inclusion if they were as follows: male, 
age < 6 years, diagnosed with congenital severe haemophilia A 
(FVIII level ≤ 1% at the time of diagnosis), had no previous use of 
purified clotting FVIII products, including commercially available 
NovoEight® (Novo Nordisk); previous exposure of ≤ 5 EDs to blood 
components, for example cryoprecipitate, fresh frozen plasma (FFP), 
was accepted.
2.3 | Treatment
For prophylaxis, each patient received a starting dose of turocto-
cog alfa of 15-50 IU/kg of body weight (BW) administered once 
weekly, which was increased gradually by the investigator and 
based on the patient's clinical profile and local treatment practices. 
Patients < 2 years old were required to start prophylaxis treat-
ment no later than after ≤ 2 bleeding episodes requiring treatment, 
or once they had reached 2 years of age, whichever came first. 
Patients ≥ 2 years old at enrolment were required to start prophy-
laxis immediately. Despite this, some patients continued to receive 
on-demand treatment for up to 23 EDs before initiating prophy-
laxis. All bleeds could be treated at home, regardless of severity. 
Individual doses for treatment of bleeds were determined by the 
investigators.
ITI treatment, if required, was initiated within 6 months (from 
inhibitor detection) and could continue for ≤24 months. Before 
any decision to initiate ITI treatment, patients could receive either 
on-demand treatment (with bypassing agents or turoctocog alfa) or 
modified prophylaxis with turoctocog alfa. The ITI treatment regi-
men was at the investigator's discretion, and patients were allowed 
to continue in the extension phase after completion of ITI treatment 
and a negative inhibitor titre (<0.6 BU).
K E Y W O R D S
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2.4 | Study endpoints and assessments
The primary endpoint was the incidence rate of FVIII inhibitors (≥0.6 
BU) during the main phase (≥50 EDs). Secondary safety endpoints 
for the main, extension and combined (main and extension) phases 
included frequency of adverse events (AEs) and serious AEs (SAEs), 
and incidence rate of FVIII inhibitors (≥0.6 BU) and high-titre inhibi-
tors (≥5 BU). Secondary efficacy endpoints included haemostatic 
response for treatment of bleeds, ABR during prophylaxis, num-
ber of infusions required per bleeding episode and consumption 
of turoctocog alfa. Haemostatic response was assessed by parents 
8 hours after the first treatment for a bleed using a predefined four-
point scale (excellent, good, moderate and none). Further details are 
provided in the Appendix S1. FVIII inhibitors (Nijmegen-modified 
Bethesda assay) and genotyping were assessed in a central labora-
tory. FVIII activity and recovery were both optional tests and not 
used to calculate endpoints and, consequently, have not been in-
cluded here.
2.5 | Statistical methods
No formal testing of statistical hypotheses was carried out, nor were 
any formal sample size calculations performed. It was expected 
that a target sample size of 50 patients completing the trial would 
adequately measure inhibitor development in the trial population. 
Consequently, 60 patients were enrolled in the trial which allowed 
for a 15% drop-out rate. The full and safety analysis sets included all 
dosed patients with data after dosing.
Incidence rates for inhibitor development during each study 
phase were calculated and an exact one-sided 97.5% upper con-
fidence limit estimated using the binomial distribution. In cases of 
inhibitor recurrence, only the first occurrence was included in the 
analyses. Additional analyses evaluated relationships between the 
incidence rate of inhibitors and different patient characteristics (eg 
race, family history of inhibitors and FVIII gene mutation type) and 
first-treatment characteristics (eg age, reason for FVIII treatment 
and intensity of treatment once initiated). Further details are pro-
vided in the Appendix S1. The protocol-defined FVIII gene mutation 
classification was later deemed incomplete, and a revised classifica-
tion was used in a post hoc analysis presented here. Patients who 
developed inhibitors were considered separately until their ITI treat-
ment was completed, and their data were evaluated and reported 
independently from the trial population overall.
The incidence rates of high-titre inhibitors were analysed in a 
similar way to the primary endpoint.
AEs and SAEs were summarized by frequency of events and fre-
quency of patients with any event.
Secondary efficacy endpoints were analysed for the main and 
combined phases using descriptive statistics. ABR and 95% confi-
dence intervals were estimated using a Poisson regression model 
allowing for over-dispersion and using (log) trial duration as offset.
3  | RESULTS
3.1 | Patient exposure and treatment
In total, 60 patients were enrolled and exposed to treatment 
(Figure 2), receiving ≥1 dose of turoctocog alfa; 58 patients received 
F I G U R E  1   Trial design. *Inhibitor testing was performed at visits 3, 4 and 5 (10-15, 20-25 and 50-55 EDs, respectively) and could be done 
at any unscheduled visit at the investigators’ discretion. Patients receiving on-demand treatment were allowed to postpone initiation of their 
prophylaxis regimen until they had experienced either a minimum of two treatment-requiring bleeds or once they had reached 2 y of age 









F I G U R E  2   Participant flow. *One patient restarted ITI 
treatment and one developed inhibitors during the extension 
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turoctocog alfa prophylactically and 49 patients (81.7%) completed 
the trial. Baseline characteristics are shown in Table 1.
3.2 | Development of FVIII inhibitors
Overall, 25 of 58 (43.1%) patients who completed the main phase, and 
therefore were included in the primary analysis, developed FVIII in-
hibitors (Table 2). Inhibitors were detected in the main phase within 
6-24 EDs (from first dose), with a mean of 14.2 EDs before their first 
positive inhibitor test (Figure 3). One patient developed an inhibitor 
before starting prophylaxis treatment. One patient developed a low-
titre inhibitor during the extension phase (after 101 EDs); therefore, 26 
patients developed inhibitors overall throughout the entire trial. High-
titre inhibitors accounted for 16 (61.5%) of the 26 inhibitor cases, with 
peak titres ranging from 5.5 to 334.6 BU. A post hoc analysis identified 
high-risk genetic mutations (ie inversions, nonsense mutations, large 
deletions and certain small deletions that result in a lack of endogenous 
FVIII production;14,15 Table 3) in 24 of the 26 inhibitor patients in the 
trial, including 15 of the 16 patients with high-titre inhibitors. Genetic 
mutations classified as ‘high risk’ carried a statistically significant risk 
for inhibitor development (P = .003); other risk factors (eg race and 
family history) were not statistically significant. Inhibitor development 
was higher in patients of Asian descent than in other racial groups and 
the incidence of inhibitor development generally increased with the 
age of the patient when treatment was first initiated (statistically non-
significant in both cases).
3.3 | Frequency of AEs and SAEs
Overall, 721 AEs were reported in 60 patients exposed to turocto-
cog alfa with a total participation in the trial of 140.1 patient-years. 
The most frequently reported SAEs are shown in Table 4. No cases of 
allergy or hypersensitivity related to turoctocog alfa were reported.
3.4 | Efficacy
A total of 402 bleeds in 52 patients on prophylaxis were reported 
during the combined phases; 98 bleeds occurred in 36 of 51 (70.6%) 
patients during the main phase, either before initiation of prophy-
laxis or development of inhibitors. Subcutaneous bleeds accounted 
for more than half (53.7%) of bleeds in patients on prophylaxis dur-
ing the combined phases.
Haemostatic response was rated as ‘excellent’ or ‘good’ for 346 
(86.1%) bleeds during prophylaxis overall (combined phases; includ-
ing missing values as failure) (see Figure S1). Five severe bleeds were 
reported in patients on prophylaxis during the main phase; for some 
patients in this group with a poor haemostatic response, inhibitors 
were detected within a few days after the bleeding episode, suggest-
ing that inhibitors may have already been present. After exclusion 
of bleeds with missing evaluations, the success rate for treatment of 
bleeds during prophylaxis was 88.5% overall and 89.6% in the main 
phase.
Patients on prophylaxis had an overall Poisson mean estimated 
ABR of 4.26 bleeds/patient/year (95% CI: 3.34-5.44), with 5.63 
bleeds/patient/year in the main phase and 3.81 bleeds/patient/year 
in the extension phase (see Figure S2). Further details of the pro-
phylaxis treatment regimens at the start and end of the main and 
extension phases are provided in Table S1. In total, 34.5% and 18.3% 
of patients reported no bleeds during prophylaxis in the main phase 
and extension phase, respectively.








Number of patients 26 34 60
Age, N (%)
0-<1 mo 3 (11.5) - 3 (5.0)
1-<6 mo 5 (19.2) 7 (20.6) 12 (20.0)
6-<12 mo 8 (30.8) 19 (55.9) 27 (45.0)
≥12 mo 10 (38.5) 8 (23.5) 18 (30.0)
Mean age at baseline 
(SD), months
10.5 (8.86) 10.0 (7.16) 10.2 (7.88)
Ethnicity
Hispanic or Latino, 
N (%)
1 (3.8) 4 (11.8) 5 (8.3)
Race (%)
White 17 (65.4) 27 (79.4) 44 (73.3)
Asian 7 (26.9) 5 (14.7) 12 (20.0)




Genotype—type of mutation,a N
High risk 24 17 41




Family history of 
haemophilia, N (%)
26 (100.0) 34 (100.0) 60 (100.0)
Yes 13 (50.0) 14 (41.2) 27 (45.0)
Family history of 
inhibitor, N (%)
13 (100.0) 14 (100.0) 27 (100.0)
Yes 1 (7.7) 4 (28.6) 5 (18.5)
Unknown 7 (53.8) 4 (28.6) 11 (40.7)
Previous exposure to blood componentsb (≤5 d), N (%)
Yes 4 (15.4) 7 (20.6) 11 (18.3)
Abbreviations: CI, confidence interval; d, days; mo, months; N, number 
of patients; SD, standard deviation.
aFVIII gene mutation analysis was conducted post hoc. 
bPatients who had prior exposure (≤5 exposure days) to blood 
components, such as cryoprecipitate or fresh frozen plasma, were 
included in the trial. 
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In total, 227 of 402 (56.5%) bleeds reported for patients on pro-
phylaxis (combined phases) were controlled with one injection of tu-
roctocog alfa; 22.6% were controlled with two injections and 7.5% 
with three injections.
3.5 | Consumption of turoctocog alfa
Patients on prophylaxis had a mean of 167.7 EDs and received a mean 
of 172.4 injections/patient. Most patients received prophylaxis once 
or twice weekly during the main phase, and many continued on these 
regimens in the extension phase. Patients who were successfully 
tolerized and subsequently entered the extension phase typically re-
ceived a higher-frequency dosing regimen, for example three times 
weekly. Patients on prophylaxis consumed a mean of 5245.9 IU/kg 
of turoctocog alfa/patient/year in the combined main and extension 
phase. Further consumption details are provided in Table 5.
3.6 | Treatment of inhibitors
Overall, 26 patients developed inhibitors in the trial. Of these, two 
patients withdrew from the trial without commencing ITI treatment 
and three patients achieved resolution of their low-titre inhibitor and 
TA B L E  2   Incidence rate of inhibitors
 
Main phase Extension phase Total
n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI
FVIII inhibitors (>0.6 BU) 25/58 (43.1) 30.2-56.8 1/33 (3.0) 0.1-15.8 26/58 (44.8) 31.7-58.5
High-titre inhibitors (≥5 BU) 16/58 (27.6) 16.7-40.9 0/33 (0.0) 0.0-10.6 16/58 (27.6) 16.7-40.9
By patient characteristics n/N (%) OR 95% CI n/N (%) OR 95% CI n/N (%) OR 95% CI
Age at first infusion of FVIII concentrate
≤5 mo 3/10 (30) 1.0 NA 1/7 (14.3) - - 4/10 (40) 1.0 NA
6-11 mo 8/22 (36.4) 1.3 0.3-6.7 0/14 (0.0) - - 8/22 (36.4) 0.9 0.2-4.0
12-18 mo 10/20 (50.0) 2.3 0.5-11.7 0/10 (0.0) - - 10/20 (50.0) 1.5 0.3-7.0
>18 mo 4/6 (66.7) 4.7 0.5-40.9 0/2 (0.0) - - 4/6 (66.7) 3.0 0.4-24.9
Mutation type
High risk 23/41 (56.1) 1.0 NA 1/18 (5.6) - - 24/41 (58.5) 1.0 NA
Low risk 1/15 (6.7) 0.1 0.0-0.5 0/14 (0.0) - - 1/15 (6.7) 0.1 0.0-0.4
Missing 1/2 (50.0) 0.8 0.0-13.4 0/1 (0.0) - - 1/2 (50.0) 0.7 0.0-12.1
Note: Percentage values are the incidence rates of inhibitor. One patient entered the extension phase but did not receive a dose of turoctocog alfa 
and was not included as ‘at risk’. Genotype testing was optional and data for 2 patients without assessment are not included.
Abbreviations: CI, confidence interval; FVIII, factor VIII; mo, months; N, number of patients at risk; n, number of patients with new inhibitor in the 
period; OR, odds ratio.
F I G U R E  3   Time to development of 
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completed the trial without ITI treatment. Of the remaining 21 pa-
tients who started ITI treatment, 14 had a high-titre inhibitor (≥5 
BU). Eighteen of the twenty-one patients (85.7%)1 completed the 
trial with a negative inhibitor titre, and three patients (14.3%) were 
withdrawn because either their inhibitor titre did not decline suffi-
ciently during ITI treatment or they remained positive for inhibitors 
after 2 years of ITI.
During ITI treatment, patients were allowed to receive up to 
200 IU/kg of turoctocog alfa daily. A variety of ITI dosing regimens 
were used, reflecting the diversity in ITI treatment practices in the 
participating centres. Of the 14 patients with high-titre inhibitors, 
11 received ITI once daily and three received ITI every second day or 
three times weekly. Six (of seven) patients with low-titre inhibitors 
received ITI every second day or three times weekly, and one patient 
received once-daily ITI treatment. ITI treatment administered three 
times weekly was generally at a low dose (approximately 50 IU/kg/
dose) compared with ITI administered daily or every second day 
(100-150 IU/kg/dose). The mean duration of ITI treatment was 
312.9 and 425.7 days for patients with low- and high-titre inhibitors, 
respectively. The median (interquartile range) time to first negative 
inhibitor test (<0.6 BU) was 140.0 (158.0) days (for the combined 
population of patients with low- and high-titre inhibitors).
In patients who developed inhibitors, 179 bleeds were reported 
in 19 patients and most were classified as mild/moderate (95.5%) 
and were caused by trauma (86%). Mean ABR was slightly higher in 
patients with inhibitors compared with those patients who did not 
develop inhibitors (6.34 bleeds/patient/year [95% CI: 3.98-10.13] vs 
4.15 bleeds/patient/year [95% CI: 3.20-5.39], respectively).
Three patients who completed ITI had recurrence of inhibitors 
during the extension phase. The first patient had a low-titre inhibitor 
initially and again on recurrence (1.7 BU) and continued to receive 
prophylaxis once weekly in the extension phase. The second patient 
had a high-titre inhibitor initially and had recurrence with a low-titre 
inhibitor (0.7 BU); they received a second round of ITI treatment. 
The third patient had a high-titre inhibitor originally and again on 
recurrence (5.8 BU) and continued to receive prophylaxis in the ex-
tension phase twice weekly. Further details are provided in Table S2.
4  | DISCUSSION
This is the first trial within the guardian clinical trial programme to 
evaluate turoctocog alfa in PUPs, a patient population that is gener-
ally at an increased risk of developing antibodies to foreign protein 
such as exogenous FVIII. Treatment with turoctocog alfa was shown 
to be effective at preventing and controlling bleeds. ABR was well 
within the range reported in other recently published PUP studies 
with rFVIII.9,10,16,17 In a prospective, open-label study of moroctocog 
alfa (N = 37 PUPs) overall mean ABR was 5.9.10 A recent postmarket-
ing surveillance study of rurioctocog alfa in PUPs (N = 114) in Japan 
reported mean ABR of 7.4 for patients with severe haemophilia A 
receiving prophylaxis.16,17 In another study, interim ABR data for 
human-cl hFVIII was 3.94 (standard deviation: 5.53).9 The dosing 
regimens used in guardian 4 reflect the standard clinical practices 
typically seen in clinics: most patients will usually receive prophy-
laxis on a lower-frequency dosing regimen in their early years.
In guardian 4, 43.1% of patients who received turoctocog alfa 
developed an inhibitor during the main phase of the trial (within 
the first 50 EDs). An inherent limitation of the study is the small 
sample size and resultant large confidence intervals. The range of 
inhibitor incidence rates in the study population recruited for guard-
ian 4 (ie PUPs) is within the range reported for rFVIII products in 
1 Data on the last 3 patients completing ITI are based on information collated from sites 
prior to the final database lock.
TA B L E  3   Incidence of inhibitors by genetic mutation
Risk level Sub-mutation N
Developed inhibitor
n (%)
High-risk Intron 22a 24 15 (62.5)
Small deletionb 7 4 (57.1)
Nonsense mutations 5 1 (20.0)
Intron 1 3 3 (100.0)
Large deletion 2 1 (50.0)
Missense mutationsa 1 0 (0.0)
Low-risk Missense mutations 6 0 (0.0)
Duplication 2 0 (0.0)
Splice site mutation 2 0 (0.0)
Large duplication 1 1 (100.0)
Large insertion 1 0 (0.0)
Small deletionb 1 0 (0.0)
Small duplication 1 0 (0.0)
Small insertionb 1 0 (0.0)
Missing Missing 2 1 (50.0)
Abbreviations: N, number of mutations; n, number of patients with a 
given mutation who developed an inhibitor.
aOne patient had two mutations (intron 22 and missense mutation); as 
the patient had both a high- and low-risk mutation, both mutations for 
this patient are listed under high risk. 
bSmall deletion and insertion outside location 1213 or 1460 were 
considered high risk. 
TA B L E  4   Most frequently reported SAEs (occurring in ≥ 5% of 
patients)
AE N % E
FVIII inhibition 25 (41.7) 27
Device-related infection 5 (8.3) 7
Traumatic haemorrhage 4 (6.7) 5
Pyrexia 4 (6.7) 4
Anaemia 3 (5.0) 3
Head injury 3 (5.0) 3
Abbreviations: AE, adverse event; E, number of SAEs; N, number of 
patients with SAEs; SAE, serious adverse event.
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other key PUP studies, such as the UKHCDO,18 CANAL,19 RODIN,20 
EUHASS21 and SIPPET22 (24.4%-44.5%).
The risk of inhibitor development varies considerably between 
minimally treated patients (MTPs) (defined as ≤ 5 EDs)23 or PTPs and 
PUPs.24 Some PUP trials have included patients (up to 56%) with a 
certain amount of prior exposure (eg 4 EDs) to FVIII concentrate;25 by 
definition, these patients are MTPs, not PUPs. By contrast, in guardian 
4, no patients had received FVIII concentrates and no more than 18.3% 
of patients had prior exposure (≤5 EDs) to blood components such 
as cryoprecipitate or FFP. Previous exposure to FVIII (endogenous or 
exogenous) will confer some degree of immunological tolerance.26 A 
recent sub-analysis from the Survey of Inhibitors in Plasma-Product 
Exposed Toddlers (SIPPET) trial showed that the inhibitor incidence 
rate during the first 5 EDs for PUPs treated with recombinant FVIII 
was 9.5%.8 Based on this analysis, MTPs with previous exposure of 
5 EDs would have an approximately 30% risk of developing inhibi-
tors, in contrast to a risk of 40% in true PUPs. Therefore, previous 
exposure to FVIII, however minimal, may affect the overall incidence 
of inhibitor development in a study population because patients who 
may develop inhibitors early would be excluded.
Older single-product PUP studies have also included patients 
with mild or moderate haemophilia25,27,28 and several of them cate-
gorized patients with a FVIII activity of <2% as ‘severe’.27 In guardian 
4, only patients with a FVIII level of ≤1% were included. These differ-
ences have considerable implications for how the results from PUP 
studies should be interpreted. The inhibitor risk for patients with 
mild/moderate haemophilia is considerably lower compared with 
those with severe haemophilia (from <5% to >30%, respectively6). It 
is also well known that even in severe patients, null vs non-null muta-
tions are associated with varying risks of inhibitor development; this 
underlies the direct inverse correlation between endogenous FVIII 
levels and inhibitor risk.29
The development of inhibitors in PUPs is a natural immune re-
sponse to foreign protein, and several factors are known to be asso-
ciated with inhibitor development.30 Large cohort studies in PUPs 
have identified the importance of modifiable risk factors for inhib-
itor development such as age at first infusion of FVIII concentrate, 
treatment intensity, treatment regimen (on-demand treatment vs 
prophylaxis), and type of FVIII concentrate.20,22,31 Non-modifiable 
risk factors include causative gene mutation, severity of disease, 
ethnicity, family history, and polymorphisms of immune response 
genes.6,31 FVIII gene mutations considered to be a high risk for in-
hibitor development include intron 22 inversion, intron 1 inversion, 
nonsense mutations, and large deletions, as well as other mutations 
resulting in a complete absence of endogenous FVIII.32,33 Genetic 
mutations are one of the strongest risk factors for inhibitor devel-
opment, and this is supported by the findings in guardian 4. Most 
patients who developed inhibitors had an underlying high-risk ge-
netic mutation which was found to be the strongest statistically 
significant risk factor for inhibitor development (P = .003). Of the 
25 patients who developed inhibitors in the main phase, 23 had a 
high-risk genetic mutation. This finding is consistent with other PUP 
studies that used similar mutation categorization.19,20
Inversions were found to be the most frequent type of muta-
tion in this trial; of the 56 patients with a known mutation type, 24 
had an intron 22 inversion and three patients had an intron 1 in-
version. Patients with an intron 22 inversion express endogenous 
FVIII protein intracellularly providing central tolerance which in 
most cases prevents the immune system from reacting to exogenous 
FVIII.34 Consequently, intron 1 and intron 22 inversions are known 
to carry only approximately 20% risk for inhibitor development.15,33 
Conversely, almost two-thirds of patients with either of these muta-
tion types in guardian 4 developed inhibitors (63%). No other inhibi-
tor risk factors were identified in this population.
No other patient or treatment characteristics (modifiable or 
non-modifiable) were shown to be associated with an increased risk 
of inhibitor development in this trial; this may be due to the small 
sample size. Patients of African descent were not represented in the 
trial. This patient population is known to have an increased risk for 
inhibitor development and a poorer response to ITI treatment com-
pared with other patient groups.35
Generally, there is a lack of consistency across PUP studies in 
the methods used for defining assay positivity, which may occasion-
ally cause false-positive results. Variation in methodology together 
with differences in patient population and statistical approach may 
account for the wide range of inhibitor rates (24.4%-44.5%) re-
ported in different PUP studies including this study.18,22 Therefore, 
it is important to consider differences in study design, sample size 
and inhibitor-testing methodologies when comparing PUP studies. 
Multiple laboratory tests are available for detecting inhibitors in 
haemophilia, and new methods for defining assay positivity have 






phase (n = 49)
Preventive treatment per year/patient
Mean 3522.0 5355.4




Preventive treatment per month/patient
Mean 293.5 446.3
Median (min.; max.) 227.1 (66; 1699) 390.1 (132; 
1101)
Preventive treatment per week/patient
Mean 68.3 103.8








Treatment of a bleed (start to stop of bleed)
Mean 98.9 86.1 96.4
Median 
(min.; max.)
54.2 (16; 1471) 48.7 (0; 803) 53.4 (0; 
1471)
Abbreviations: Max., maximum; Min., minimum.
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been suggested; however, there are still ongoing challenges in the 
areas of assay standardization and testing in the presence of modi-
fied and novel treatment products.36
In guardian 4, treatment with turoctocog alfa was effective at 
both preventing and stopping bleeds. The majority of patients who 
developed inhibitors in this study had a high-risk genetic mutation, 
and many of these had high-titre inhibitors. In total, 18 patients 
(85.7%)2 who developed inhibitors and commenced ITI therapy sub-
sequently had a negative inhibitor titre. Treatment with turoctocog 
alfa was well tolerated and inhibitor development was within the 
expected range for PUPs with severe haemophilia A.
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